Policy

Five things for pharma marketers to know: Wednesday, June 28, 2017

Five things for pharma marketers to know: Wednesday, June 28, 2017

By

Lawmakers delay healthcare bill vote; Merck affected by cyberattack; more young people are having strokes

Five things for pharma marketers to know: Friday, June 23, 2017

Five things for pharma marketers to know: Friday, June 23, 2017

By

Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

What marketers need to know about tax reform, off-label promotion, pricing

What marketers need to know about tax reform, off-label promotion, pricing

By

The ad-tax deduction is likely once again on the table.

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

By

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies

Five things for pharma marketers to know: Friday, March 3, 2017

Five things for pharma marketers to know: Friday, March 3, 2017

By

Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Friday, February 10, 2016

Five things for pharma marketers to know: Friday, February 10, 2016

By

Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS

Five things for pharma marketers to know: Wednesday, February 1, 2017

Five things for pharma marketers to know: Wednesday, February 1, 2017

By

Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

By

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Five things for pharma marketers to know: Wednesday, December 14, 2016

Five things for pharma marketers to know: Wednesday, December 14, 2016

By

Obama signs 21st Century Cures Act into law; the FDA approved 19 new drugs in 2016; Sanofi in talks to acquire Actelion

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

By

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

What's Next for the FDA During the Trump Administration

What's Next for the FDA During the Trump Administration

By

Expect major changes in the way the FDA does business with drug companies after the Trump administration takes over in January.

5 questions raised at the FDA's off-label hearing

5 questions raised at the FDA's off-label hearing

By

The FDA asked questions about the risks and benefits of allowing off-label communications.

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

By

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

Timeline of a crisis: How Mylan responded to the EpiPen controversy

Timeline of a crisis: How Mylan responded to the EpiPen controversy

By

Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike — its response was seen as too little, too late.

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.

Five things for pharma marketers to know: Wednesday, September 7, 2016

Five things for pharma marketers to know: Wednesday, September 7, 2016

By

BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan

Five things for pharma marketers to know: Tuesday, August 30, 2016

Five things for pharma marketers to know: Tuesday, August 30, 2016

By

Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler

Five things for pharma marketers to know: Wednesday, August 10, 2016

Five things for pharma marketers to know: Wednesday, August 10, 2016

By

A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion

Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

By

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Clinton or Trump? Either Way, Change Is Coming

Clinton or Trump? Either Way, Change Is Coming

Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.

DTC Report 2016: Gut Check

DTC Report 2016: Gut Check

By

DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.

Pharma CEOs defend R&D model to investors

Pharma CEOs defend R&D model to investors

By

Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.

Must biosimilar names be distinct? No, experts argue

Must biosimilar names be distinct? No, experts argue

Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.

Docs haven't mellowed on DTC, snap poll suggests

Docs haven't mellowed on DTC, snap poll suggests

By

The FDA wants to know how physician attitudes towards direct-to-consumer advertising have evolved since the agency last asked them, in 2002. If a snap poll by CMI/Compas is any indication, drug companies probably won't like the answers.

Q&A: BIO's Jim Greenwood

Q&A: BIO's Jim Greenwood

By

BIO chief Jim Greenwood talks policy priorities and previews the group's International Convention, now underway in Chicago.

Obama budget would bleed pharmas

By

The White House released its proposed budget for the 2014 fiscal year this morning, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.

For Obama's head-less CMS, third time's the charm

For Obama's head-less CMS, third time's the charm

By

Acting administrator Marilyn Tavenner seems on track for confirmation, with the blessings of all industry stakeholders

Court could punt "Pay for Delay" back to Congress

By

Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called "pay for delay" settlements hangs in the balance.